2'-ISOTHIOCYANATO-2-METHOXY-3,4'-BIPYRIDINE

Catalog No.: 
ACRIRX382
CAS No.: 
1192814-86-0
Molecular Formula: 
C12H9N3OS
Molecular Weight: 
243.29
2'-ISOTHIOCYANATO-2-METHOXY-3,4'-BIPYRIDINE structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g95%$855.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2'-ISOTHIOCYANATO-2-METHOXY-3,4'-BIPYRIDINE
IUPAC Name2'-isothiocyanato-2-methoxy-3,4'-bipyridine
MDL No.MFCD30530697
Molecular FormulaC12H9N3OS
Molecular Weight243.29
SMILESCOC1=NC=CC=C1C2=CC(N=C=S)=NC=C2
InChI KeyUCMJVPUVABQMFV-UHFFFAOYSA-N
Synonym3,4'-Bipyridine, 2'-isothiocyanato-2-methoxy-
CAS No.1192814-86-0

Safety Data

Pictogram
ToxicHealth hazard
Signal Word
Gefahr
Hazard Statement(s)
H301-H315-H319-H334-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P284-P301+P310+P330-P302+P352-P304+P340+P312-P305+P351+P338-P332+P313-P337+P313-P342+P311-P362+P364-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACRIRX382 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Plus
  5. ACDRJG518 route compound structure diagram
    ACDRJG518102368-13-8In Stock
  6. Then
  7. ACRIRX382 route product structure diagram
    ACRIRX3821192814-86-0
Inquiry

2. ACRIRX382 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACRIRX382 route product structure diagram
    ACRIRX3821192814-86-0
Inquiry

3. ACRIRX382 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACRIRX382 route product structure diagram
    ACRIRX3821192814-86-0
Inquiry

Comments (0)